Barinthus Biotherapeutics
BRNS
14 hedge funds and large institutions have $7.89M invested in Barinthus Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
8% more funds holding
Funds holding: 13 → 14 (+1)
3.41% more ownership
Funds ownership: 19.35% → 22.76% (+3.4%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
84% less capital invested
Capital invested by funds: $48.3M → $7.89M (-$40.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$49.4K |
| 2 |
GS
GTS Securities
New York
|
+$48.2K |
| 3 |
Renaissance Technologies
New York
|
+$5.21K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$130 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.21K |
| 2 |
Morgan Stanley
New York
|
-$788 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MGP
1
M&G plc
London,
United Kingdom
| $5.2M | – | – | – |
|
|
HH
2
HSG Holding
Na,
Hong Kong
| $1.16M | – | – | – |
|
|
GP
3
GLR Partners
Columbia,
Maryland
| $707K | +$819K | +1,243,377 | New |
|
|
DF
4
DC Funds
Mclean,
Virginia
| $365K | – | – | – |
|
|
RC
5
Rangeley Capital
New Canaan,
Connecticut
| $90.7K | +$49.4K | +75,024 | +89% |
|
|
6
Renaissance Technologies
New York
| $85.9K | +$5.21K | +7,900 | +6% |
|
|
JHU
7
Johns Hopkins University
Baltimore,
Maryland
| $69.6K | – | – | – |
|
|
8
Citadel Advisors
Miami,
Florida
| $68.1K | +$130 | +197 | +0.2% |
|
9
Baird Financial Group
Milwaukee,
Wisconsin
| $60.3K | – | – | – |
|
|
GS
10
GTS Securities
New York
| $41.9K | +$48.2K | +73,210 | New |
|
11
HighTower Advisors
Chicago,
Illinois
| $21.3K | – | – | – |
|
12
RhumbLine Advisers
Boston,
Massachusetts
| $6.68K | – | – | – |
|
13
Geode Capital Management
Boston,
Massachusetts
| $6.62K | – | – | – |
|
|
14
Morgan Stanley
New York
| $1.26K | -$788 | -1,196 | -35% |
|
|
15
UBS Group
Zurich,
Switzerland
| – | -$2.21K | -3,152 | Closed |
|
BRNS Hedge Fund Activity: Q1 2026 in Review
14 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q1 2026, worth a combined $7.89M — down 84% from $48.3M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BRNS positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Rangeley Capital, adding an estimated $49.4K. The largest seller was UBS Group, exiting entirely with an estimated $2.21K sold.
- 14 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q1 2026, up from 13 in Q4 2025.
- Funds reported $7.89M of Barinthus Biotherapeutics stock for Q1 2026, down 84% quarter-over-quarter.
- 2 funds opened new Barinthus Biotherapeutics positions in Q1 2026 and 1 closed out, a net change of +1 holder.
- The largest Barinthus Biotherapeutics buyer in Q1 2026 was Rangeley Capital, an estimated $49.4K added.
- The largest Barinthus Biotherapeutics seller in Q1 2026 was UBS Group, an estimated $2.21K sold.
Based on aggregated 13F filings for Q1 2026.